Protocol Summary: Trio (ACTG5377) is a Phase I, first-in-human, ascending-dose study of a tri-specific broadly neutralizing antibody, in participants living with HIV. This trial will look at a human-made antibody called SAR441236. Unlike the antibodies created by a person’s immune system that attach to HIV at one part, SAR441236 has […]